Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study
| Autor: | Jing-Jie Zhang, Wei Jin, Jun Qian, Yueyin Pan, Lin Lin, Meng-Hao Dong, Benjie Shan, Da-Bing Huang, Jian Chen, Xinghua Han, Xia-Bo Shen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Chemotherapy medicine.medical_specialty Cardiotoxicity Univariate analysis business.industry medicine.medical_treatment Retrospective cohort study medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer chemotherapy Breast cancer 030220 oncology & carcinogenesis Internal medicine medicine Original Article Surgery skin and connective tissue diseases Adverse effect business Epirubicin medicine.drug |
| Zdroj: | Gland Surg |
| ISSN: | 2227-8575 2227-684X |
| DOI: | 10.21037/gs-20-647 |
| Popis: | BACKGROUND: Neoadjuvant chemotherapy (NAC) has become the best comprehensive treatment choice for breast cancer. Epirubicin is a crucial drug widely used in breast cancer chemotherapy, but it is often used with a reduced dosage in NAC for Chinese patients for its notable cardiotoxicity and frequent adverse events. This study aimed to investigate the efficacy and safety of standard-dose epirubicin in NAC for Chinese breast cancer patients retrospectively. METHODS: We retrospectively collected clinicopathological parameters of breast cancer patients who underwent epirubicin-based NAC and a later surgery from three separate medical centers. Patients were divided into standard-dose and low-dose groups according to the epirubicin dose. The pathological complete response (pCR) rate, as the main therapeutic outcomes, and the incidence of adverse events were recorded and compared. RESULTS: The pCR rate of the standard-dose group was 41.2%, while the low-dose group was 10.1% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|